By Counterforce Health Team in Xenpozyme (olipudase alfa-rpcp) —

How to Get Xenpozyme (Olipudase Alfa) Covered by Cigna in California: Prior Authorization, Appeals, and IMR Success Strategies

Quick Answer: Xenpozyme (olipudase alfa-rpcp) requires prior authorization through Cigna's specialty pharmacy partner Accredo. You'll need confirmed ASMD diagnosis with enzyme testing, specialist prescription, and documented medical necessity. If denied, California's Independent Medical Review (IMR) has a 50-65% success rate for rare disease drugs. First step: have your doctor submit PA through CoverMyMeds or call 1-800-882-4462.

Table of Contents

Plan Types & What They Mean for Coverage

Your Cigna plan type affects how you access Xenpozyme, but the core requirements remain consistent across California.

HMO Plans: You'll need a referral from your primary care doctor to see the specialist who prescribes Xenpozyme. The specialist must be in Cigna's network, and all prior authorization flows through your assigned PCP initially.

PPO Plans: You can see any specialist directly without referrals, but staying in-network saves significantly on costs. Out-of-network specialists can still prescribe, but your cost-share will be higher.

EPO Plans: Like PPO for specialist access, but with no out-of-network coverage except for emergencies. Ensure your metabolic specialist and infusion center are in Cigna's network.

All plan types route specialty drugs like Xenpozyme through Accredo specialty pharmacy, Cigna's preferred partner.

Formulary Status: Tier 5 Specialty

Xenpozyme sits on Tier 5 (Specialty) in Cigna's formulary—the highest cost tier reserved for complex, high-cost medications. This placement means:

  • Coinsurance applies: You pay a percentage (typically 25-40%) rather than a flat copay
  • Prior authorization required: No exceptions for any indication
  • Specialty pharmacy mandatory: Cannot be filled at retail pharmacies
Note: There are no FDA-approved alternatives for ASMD, so step therapy typically doesn't apply—but Cigna may still require documentation of supportive care attempts.

Coverage Requirements Table

Requirement What It Means Where to Verify
PA (Prior Authorization) Doctor must submit clinical justification Cigna PA portal
MO (Medical Office) May require administration monitoring Plan-specific policy document
NDS (Non-Delegated Specialty) Cigna reviews directly, not third party Cigna specialty drug list

Prior Authorization Requirements

Getting PA approval requires specific documentation that proves medical necessity for ASMD treatment.

Required Documentation Checklist

Diagnosis Confirmation:

  • Acid sphingomyelinase enzyme activity <10% of normal control
  • Genetic testing showing SMPD1 gene variants (supportive)
  • Clinical evaluation documenting ASMD symptoms

Clinical Justification:

  • Specialist prescription from geneticist, metabolic specialist, or hematologist
  • Documentation of non-CNS manifestations (Xenpozyme doesn't treat brain involvement)
  • Baseline assessments: liver/spleen size, lung function, platelet counts
  • Treatment goals and monitoring plan

Prior Treatments:

  • Record of supportive care attempts where applicable
  • Documentation why other interventions are insufficient

Step-by-Step PA Submission

  1. Prescriber submits PA via CoverMyMeds, ExpressPAth, or by calling 1-800-882-4462
  2. Include all required documents: diagnosis confirmation, clinical notes, treatment plan
  3. Cigna reviews within 72 hours (24 hours for urgent cases)
  4. Approval flows to Accredo for prescription fulfillment
  5. Patient receives setup call from Accredo within 1-2 business days
Tip: Submit PA and prescription simultaneously to avoid delays. Accredo cannot begin patient setup until both are received.

Specialty Pharmacy Process

Xenpozyme is only available through select specialty pharmacies, with Cigna members typically using Accredo.

Patient Setup Process

Initial Contact: Accredo calls within 1-2 days of PA approval to:

  • Verify insurance benefits and copay responsibility
  • Schedule first infusion at approved site
  • Coordinate with home health or infusion center
  • Provide patient education materials

Site of Care Requirements:

  • Preferred: Home infusion, physician office, or independent infusion center
  • Hospital outpatient: Only if dose escalation phase, history of severe reactions, or clinical instability requiring monitoring
  • Documentation needed: Medical justification for hospital-based infusion

Ongoing Support: Accredo provides:

  • Medication delivery coordination
  • Insurance benefit verification
  • Prior authorization renewals
  • Patient adherence support

Cost-Share Basics

As a Tier 5 specialty drug, Xenpozyme involves significant cost-sharing. Understanding your specific plan helps with financial planning.

Typical Cost Structure:

  • Deductible: May apply before coinsurance kicks in
  • Coinsurance: 25-40% of total drug cost (varies by plan)
  • Out-of-pocket maximum: Annual cap on your total costs

Cost Example (verify with your plan):

  • Xenpozyme WAC: ~$7,576 per 20mg vial
  • Monthly cost: $15,000-30,000+ depending on weight-based dosing
  • Your 30% coinsurance: $4,500-9,000+ per month before hitting out-of-pocket max

Financial Assistance Options

  • Sanofi Patient Support: Xenpozyme.com offers copay assistance and patient access programs
  • California state programs: Income-based premium assistance through Covered California
  • Nonprofit foundations: Organizations supporting rare disease patients with medication costs

Appeals Playbook for California

California offers robust appeal rights, especially for rare disease medications. Success rates are significantly higher than internal plan reversals.

Internal Appeal Process

Timeline: File within 180 days of denial How to submit:

  • Online: Cigna member portal
  • Mail: Address provided in denial letter
  • Phone: Member services number on insurance card

Required documents:

  • Completed appeal form
  • Copy of denial letter
  • Medical records supporting necessity
  • Physician letter of medical necessity

Review timeline: Cigna has 60 days to respond

Independent Medical Review (IMR)

If Cigna upholds the denial, California residents can request IMR through the Department of Managed Health Care (DMHC).

Success rates: 50-65% of IMRs involving specialty/rare disease drugs result in overturned denials

How to file:

  1. Wait for final internal denial from Cigna
  2. Submit IMR application within 6 months at healthhelp.ca.gov
  3. Include all medical records and specialist recommendations
  4. DMHC assigns independent reviewers within specialty
  5. Decision within 45 days (7 days for expedited)

Cost: Free to patients—insurers pay all IMR fees

From our advocates: We've seen IMR success when families include peer-reviewed studies about ASMD progression and detailed letters from metabolic specialists explaining why Xenpozyme is the only FDA-approved option. The independent reviewers often have deeper rare disease expertise than internal plan reviewers.

Common Denial Reasons & Solutions

Understanding typical denial patterns helps strengthen your initial submission and appeals.

Denial Reason How to Address Required Documentation
Insufficient diagnosis documentation Submit enzyme assay results ASM activity <10% of control, genetic testing
Request for CNS disease treatment Clarify non-CNS manifestations only Clinical notes specifying liver, lung, spleen involvement
Lack of specialist prescription Get referral to appropriate specialist Geneticist, metabolic specialist, or hematologist
Missing monitoring plan Provide detailed treatment protocol Baseline assessments, follow-up schedule
Site of care restrictions Justify hospital infusion if needed Document dose escalation or reaction history

Medical Necessity Letter Template

Your specialist's letter should include:

  • Patient background: Age, diagnosis confirmation, symptom severity
  • Clinical rationale: Why Xenpozyme is medically necessary
  • Treatment goals: Expected outcomes and monitoring plan
  • Alternative analysis: Why other approaches are insufficient
  • FDA approval reference: Cite label for ASMD indication

When to Request IMR

Don't wait—California's IMR process is your strongest tool for overturning denials.

Best candidates for IMR:

  • Clear ASMD diagnosis with proper testing
  • Specialist support for treatment necessity
  • Failed internal appeal with Cigna
  • Progressive disease requiring intervention

Preparing for IMR:

  • Gather comprehensive records: All diagnostic tests, specialist consultations, treatment history
  • Get updated specialist letter: Specifically addressing Cigna's denial reasons
  • Include peer-reviewed evidence: Studies supporting Xenpozyme effectiveness in ASMD
  • Document disease progression: Show why treatment cannot be delayed

Timeline management:

  • Internal appeal: Up to 60 days
  • IMR filing deadline: 6 months from final denial
  • IMR decision: 45 days standard, 7 days expedited

Contact DMHC Help Center at 888-466-2219 for assistance with filing.

FAQ

How long does Cigna prior authorization take in California? Standard PA decisions within 72 hours; urgent cases within 24 hours. Complex cases may require additional clinical review.

What if Xenpozyme is listed as non-formulary on my plan? File a formulary exception request with clinical justification. Since there are no FDA-approved alternatives for ASMD, exceptions are often approved.

Can I request expedited review if my condition is worsening? Yes—both Cigna internal appeals and California IMR offer expedited pathways for urgent medical situations.

Does step therapy apply since I haven't tried other treatments? Typically no, since Xenpozyme is the only FDA-approved treatment for ASMD. However, Cigna may require documentation of supportive care attempts.

What happens if I move from another state to California? California residents gain access to IMR regardless of where treatment was initially denied. Previous appeals in other states don't reset California deadlines.

How much will Xenpozyme cost with Cigna coverage? Costs vary significantly by plan. Expect 25-40% coinsurance until you reach your annual out-of-pocket maximum. Contact Cigna member services for specific estimates.

Getting expert help with insurance appeals: Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies, then drafts point-by-point rebuttals aligned to each payer's specific requirements—including the complex prior authorization criteria that specialty drugs like Xenpozyme often face.

Whether you're navigating Cigna's initial PA process or preparing for California's IMR, having the right documentation and understanding payer-specific workflows can make the difference between approval and prolonged delays. For complex cases involving rare disease treatments, consider working with advocates who understand both the clinical evidence and the insurance landscape.

Sources & Further Reading

This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage determinations. Coverage policies and requirements may change; verify current information with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.